P rodrug strategies have been widely used to address delivery problems with pharmaceuticals 1 . Essentially, all such approaches have one goal-to deliver the drug to the desired location at a sufficiently high concentration. Prodrug efforts focused on improving physicochemical properties allow for enhanced permeability and solubility. Site-selective activations allow for targeting based on environmental factors such as pH (ref. 2 ), unique redox chemistry including levels of H 2 O 2 (ref. 3 ), glutathione 4 and other thiol species 5 , and elevated levels of enzymes such as esterases 6,7 , proteases 8 and phosphatases 9 . In addition, gut bacteria also present unique redox chemistry and an active enzymatic environment for site-selective targeting 10 . In recent years, targeted drug delivery has quickly gained attention, with some remarkable success, especially in the field of cancer, where the goal is to minimize toxicity 11 . For example, antibody-drug conjugates (ADCs) enable the targeted delivery of drugs to a desired site 12, 13 . There are many other targeting molecules that can be used to home in on biomarkers such as the high-affinity folate receptor 14 , carbohydrate biomarkers 15 and prostate-specific membrane antigen 16 . Such targeted approaches work very well in enriching the concentration of drug conjugates andprodrugs at desired sites. However, targeted release after enrichment remains a challenge.
Results
To establish the proof of concept we designed two pairs of prodrugrelease trigger partners that can undergo a bioorthogonal reaction with tunable release rates, which should set the stage for subsequent release of a drug moiety. For the drug moiety we chose two biologically and clinically relevant agents, the chemotherapeutic genotoxin doxorubicin (Dox) and the gasotransmitter carbon monoxide (CO), as model drugs. These two examples have distinctly different properties and delivery challenges. Doxorubicin and CO have half-maximum inhibitory concentration (IC 50 ) values generally in the low micromolar to high nanomolar range, depending on the cell lines used and drug exposure times. For the first pair of prodrugtrigger partners we used tetrazine-cyclooctyne chemistry as the prodrug-trigger pair for the click reaction 32, 33 , a lactonization reaction of the cycloaddition intermediate for drug release 34 and mitochondria targeting as a way to achieve enrichment, as discussed in the section 'click, cyclization and release system' 35 . Specifically, tetrazines are known to react with transcyclooctene 36, 37 and strained cyclooctyne 32, 33 with second-order rate constants ranging from 0.0001 M −1 s −1 to more than 1,000 M −1 s −1 . As a proof-of-principle study we contemplated a scenario where the prodrug is used at a concentration of 10 μ M in cell culture, without cytotoxicity, until triggered release is achieved based on control by reaction kinetics. For this design we desired the second-order rate constant to be below 0.25 M −1 s −1 , which would result in the first half-life (t 1/2 ) being over 100 h without enrichment at 10 μ M. Triphenylphosphonium (TPP) conjugation is known to enrich its payload to about 500 μ M Controlled activation is a critical component in prodrug development. Here we report a concentration-sensitive platform approach for bioorthogonal prodrug activation by taking advantage of reaction kinetics. Using two 'click and release' systems, we demonstrate enrichment and prodrug activation specifically in mitochondria to demonstrate the principle of the approach. In both cases, the payload (doxorubicin or carbon monoxide) was released inside the mitochondrial matrix following the enrichment-initiated click reaction. Furthermore, mitochondria-targeted delivery yielded substantial augmentation of functional biological and therapeutic effects in vitro and in vivo when compared to controls, which did not result in enrichment. This method is thus a platform for targeted drug delivery that is amenable to conjugation with a variety of molecules and is not limited to cellsurface delivery. Taken together, these two 'click and release' pairs clearly demonstrate the concept of enrichment-triggered drug release and the critical feasibility of treating clinically relevant diseases such as acute liver injury and cancer.
Enrichment-triggered prodrug activation demonstrated through mitochondria-targeted delivery of doxorubicin and carbon monoxide
Click, cyclization and release system. We first studied the chemical feasibility of the system with Dox as the model drug. Two components of this drug release system were synthesized: alkyne triggers (ATs, 1-3) with an appropriately positioned hydroxyl group to initiate lactonization, model tetrazine prodrugs (TPs, 4 and 5), and tetrazine-linked prodrugs of Dox (6 and 9; Table 1 ). Tetrazine conjugate (5) with a dansyl amine was prepared to take advantage of the strong fluorescence of the dansyl amine as a marker to easily monitor and also check the feasibility of the click, cyclization and release (CCR) sequence of events for aminecontaining prodrugs.
As a first step we studied the basic chemical feasibility of the proposed approach. Prodrugs 5 or 6 (25 μ M) were treated with alkynes 1, 2 or 3 at different concentrations at room temperature or 37 °C, and we monitored prodrug consumption and the release of the parent drug by high-performance liquid chromatography (HPLC) ( Table 1) . Three issues were examined in this study: (1) cycloaddition regiochemistry, (2) the substituent effect at the R 1 position and (3) the effect of the drug on the reaction rates and regiochemistry.
On the issue of regiochemistry, one can see from Table 1 that the cycloaddition chemistry has two possible regioisomeric products, but only one would lead to lactonization and drug release. For the strategy to work, it is critical that the correct regioisomer (7b) is the predominant product. Fortuitously, it was found that more than 80% Dox or dansyl amine was released within 48 h of prodrug treatment with alkyne 2 or 3. These results indicate that the regiochemistry of the inverse electron demand Diels-Alder reaction (DA inv ) is such that it favours the reaction leading to 7b, with the hydroxyl group on the cyclooctyne positioned on the same side of the amide group linked to the parent drug. This allows for subsequent lactonization and drug release. To acquire initial insight into the observed regiochemistry, we performed theoretical calculations. Specifically, we used methods reported in ref. 32 to calculate the possible transition state(s) and activation energies for two regioisomers ( Supplementary  Fig. 3 ). Schematic representations of the energy profiles for the tetrazine alkyne reactions are shown in Supplementary Fig. 3 . To simplify the calculation process, we used tetrazine 10 and alkyne 2 as models 32 . The results show that the activation energy for the first step of the DA inv between 10 and 2 via transition state TS1b is 17.1 kcal mol −1 , as compared to 19.0 kcal mol −1 for the reaction via transition state TS1a. The qualitative difference in activation energy correlates well with our observed regiochemistry outcome.
There are several reasons why we need to understand the effect of the R 1 group on the alkyne trigger in this project. First, we are interested in understanding the factors that would allow us to tune the reaction rate. It is easy to intuitively understand that the R 1 group will have an effect on both the DA inv reaction and the subsequent lactonization. Second, for eventual applications, we need to conjugate both the tetrazine and alkyne to a targeting moiety. This means that we need a 'handle' for this conjugation chemistry. For the tetrazine part, this can be accomplished easily through the phenolic hydroxyl group. For the cyclooctyne we need to introduce an additional handle for the conjugations. For this reason, the R 1 group is essential as a handle for further conjugation. Thus, we need to understand the substituent effect at this position. It was found that a methyl group or a benzyl group significantly reduced the rate of the DA inv reaction. For example, when R 1 was a hydrogen, the second-order rate constant was 0.25 M −1 s −1 at room temperature and 1.9 M −1 s −1 at 37 °C when the dansyl-amine prodrug 5 was used. In comparison, the second-order rate constant was 0.0075 M −1 s −1 and 0.021 M −1 s −1 at room temperature and 37 °C, respectively, for alkyne 2 with a methyl substituent, and 0.042 M −1 s −1 and 0.14 M −1 s −1 at room temperature and 37 °C, respectively, for alkyne 3 with a phenyl substituent. These results indicate that the DA inv reaction rates can easily be tuned over a range of more than 30-fold by using different R 1 groups on the alkyne. Additionally, varying the temperature from room temperature to 37 °C can afford further 3-to 10-fold variations in the reaction rates. The reaction rate (0.25 M −1 s −1 ) between 9 and 3b is similar to that for the reaction between 6 and 3a (0.17 M −1 s −1 ), confirming that introduction of the TPP moiety does not significantly affect the reaction kinetics. As discussed earlier, the second-order rate constant was targeted to be below 0.25 M −1 s −1 . Here, the range of second-order rate constants that can be tuned falls exactly where needed. It should also be noted that the R 1 substituent accelerated the rate of lactonization, as expected due to added conformational constraints. Therefore, NaTUre CHemIsTry all the reaction studies described thus far clearly demonstrate one thing-the designed CCR system can be used as a viable bioorthogonal prodrug for ETR.
Regarding the third issue-the effect of the drug moiety on the reaction outcomes-it was found that dansyl-amine prodrug 5 and Dox prodrug 6 did not show statistically significant differences in terms of reaction rates. For example, the second-order rate constants for the reaction of alkyne 1 with tetrazines 5 and 6 at 37 °C were 1.9 and 2.1 M −1 s −1 , respectively. Similarly, the second-order rate constants for the reaction of alkyne 3b with tetrazine 5 and 6 at 37 °C were 0.14 and 0.19 M −1 s −1 , respectively. These results are to be expected because the drug portion is positioned away from all reaction centres, and thus would not be expected to have a major effect on the reaction rates. The only issue is that if the lactonization rate is slow, it may only lead to partial drug release within a reasonable period of time. This is the case with alkyne trigger 1. For example, only 60% dansyl-amine and 20% Dox were detected after treating prodrugs with alkyne 1 (1 mM) for 48 h. This low Dox recovery percentage was probably a result of the slow lactonization rate of 7b (t 1/2 = 24 h) when R 1 was hydrogen, and decomposition of Dox in phosphate-buffered saline (PBS) (t 1/2 = 50 h) 39 . In contrast, with alkyne 2, the lactonization rate was so fast that the HPLC method did not detect accumulation of the intermediate (CI). This also led to 85-90% release of the active drug at the 48 h point. For Table 1 | Chemical structure of CCR systems and evaluation of the reaction kinetics of the CCR system 
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alkyne 3, the situation was similar, with 80-90% drug release. All these results indicate the importance of the R 1 group, not only for tethering the targeting molecule, but also for achieving an improved lactonization rate. In addition to the three chemical feasibility issues discussed above, we were also interested in understanding the stability of the tetrazine-linked prodrugs in the presence of high concentrations of thiol species, due to the electron-deficient nature of the tetrazine moiety. It is important to note that we did not encounter stability problems ( Supplementary Table 4 ).
In vitro assessment of the CCR system. Next, we were interested in testing the drug delivery system in a cellular environment. We first chose alkynes 1 and 3b. HeLa cells were incubated with different concentrations of Dox prodrug and alkynes, or doxorubicin, for 48 h at 37 °C. The IC 50 values are shown in Table 2 . After modification, Dox prodrug 6 lost its activity, with an IC 50 value well over 100 μ M, while the IC 50 of the parent drug Dox was about 1.0 μ M. These results were expected and desirable because the activity of the prodrug means that it will not be cytotoxic before Dox is released through the CCR process. As designed, the IC 50 of Dox prodrug 6 is about 1.5 μ M in the presence of 50 μ M alkyne 1 and 2.0 μ M in the presence of 50 μ M alkyne 3b, indicating efficient release of the parent drug, Dox, by alkynes 1 and 3b.
Having established a well-defined release system, we next examined the feasibility of using reaction kinetics to control drug release. Our goal was thus to target and enrich the prodrug at a particular location within the mammalian cell. It is well known that folic acid, Arg-Asp-Asp (RGD) and many other molecules can target cancer and can be used for drug delivery 1 . We chose mitochondrion targeting through the use of a well-known TPP moiety, which is known to be enriched in mitochondria by approximately 100-to 500-fold 38 . We elected to use mitochondria targeting because this can easily be assessed in a cell culture system. Thus, we conjugated the tetrazine prodrug and the alkyne trigger with TPP to give 9 and 3b, respectively. HeLa cells were treated with 10 μ M or 20 μ M TPP alkyne 3b and various concentrations of TPP-Dox prodrug 9 (0, 1.2, 2.5, 5 and 10 μ M) for 48 h. It is clear that the IC 50 value (~1.5 μ M) for TPP Dox 9 in the presence of 20 μ M of TPP alkyne 3b is much lower than that of its non-TPP conjugated counterpart Dox prodrug 6 (~10 μ M) in the presence of 20 μ M alkyne 3a ( Fig. 2a ). A similar trend was seen when the alkyne concentration was decreased to 10 μ M. For example, the IC 50 for TPP-Dox prodrug 9 was about 2 μ M in the presence of 3b, while the IC 50 for Dox prodrug 6 was well over 10 μ M in the presence of 10 μ M of the alkyne trigger 3a (Fig. 2b ). As controls, both IC 50 values of 9 and 3b alone are higher than 40 μ M, and treatment with 20 μ M of alkyne 3a or 3b alone had no effect on cell viability. These dose-dependent results strongly support the underlying hypothesis that conjugation with TPP (3b and 9) allows for the enhanced release of Dox through enrichment of the prodrug in mitochondria, which subsequently leads to an enhanced bimolecular reaction rate and facilitates CCR-mediated activation of the prodrug. Without this enrichment, the reaction is expected to be slow, resulting in a lower level of active Dox being released. Specifically, the second-order rate constant of the reaction between Dox prodrug 6 and alkyne 3a was determined to be 0.17 M −1 s −1 , with the first t 1/2 at a 10 μ M concentration of 6 and 10 μ M concentration of 3a being about 163 h. These results also mean that only 22% of the drug is released at the 48 h time point. If the concentrations of both the tetrazine prodrug (9) and alkyne (3b) are enriched to 500 μ M in the mitochondria, the first t 1/2 of the reaction would be 2.0 h ( Supplementary Fig. 2.1 ), which means almost complete Dox release at the 48 h time point. As a consequence, major differences in the apparent potency of the two prodrugs were observed with and without conjugation to TPP. Therefore, we conclude that enrichment in the mitochondria indeed led to triggered release of the drug, as designed. The same concept is applicable to the delivery of drugs through other targeting approaches such as receptormediated drug delivery.
CO delivery system via click chemistry.
To demonstrate the general applicability of the 'enrichment to release' concept for prodrug activation, we designed a second system, which uses different chemistry and a different drug component. Specifically, we designed a bioorthogonal reaction cyclopentadienone-alkyne pair for the targeted delivery of CO to mitochondria (Table 3 ). CO has been widely accepted as an endogenous signalling molecule with potent physiological and therapeutic importance on par with that of nitric oxide [40] [41] [42] [43] [44] [45] . Mitochondria have been proposed to be a major site for action for CO 46 . Indeed, metal-based CO-releasing molecules (CORMs) have been developed that release CO extracellularly, rapidly diffuse into a cell, and influence mitochondrial function in part by binding to haem-containing oxidases on their inner membrane 46, 47 . Later, organic CO prodrugs were reported with the ability to release CO extracellularly 17, 23, 48 . Thus, targeting mitochondria would allow for CO release at the site of action. Given its high diffusivity, CO should be able to subsequently traverse out of the mitochondria into the cytosol to modulate additional functional effects. Previously, we 
NaTUre CHemIsTry
successfully developed metal-free CO prodrugs by employing the click reaction between cyclopentadienone and a strained alkyne (for example, BCN) 18 . For mitochondrial targeted delivery, we conjugated both components of the Diels-Alder reactants with TPP as the targeting moiety for mitochondria for ETR (Table 3) 49 . Additionally, to facilitate visualization of the intracellular click reaction and CO release, a naphthalene group was attached to the 3,4 position of the dienone ring to enable fluorescence turn-on on clicking these two components 23 . Compounds 21 and 22 were readily synthesized ( Table 3 ). With these compounds in hand, we initially confirmed CO release from the click reaction between 21 and 22 using the widely accepted CO-myoglobin assay ( Supplementary Fig. 8 ). We next tested their second-order rate constants by monitoring the blue fluorescence of the click products. Much like the previous CCR system, the ligation of TPP did not significantly affect the reaction kinetics between the alkyne and dienone compound ( Table 3) . We next probed whether compounds 21b and 22b could be used for targeted delivery of CO to mitochondria. In this case, the enrichment and release process can be conveniently monitored by fluorescence turn-on following the click reaction 17, 23 . To test this, RAW264.7 macrophages were simultaneously co-treated with 21b and 22b at different concentrations of 1 and 5 μ M for 3 h and imaged under the 4,6-diamidino-2-phenylindole (DAPI) channel (absorption at 358 nm and emission at 461 nm). RAW264.7 cells co-treated with 21a and 22a were used as controls.
As shown in Fig. 3a,b , RAW264.7 cells co-treated with 21a and 22a showed no fluorescence signal at either 1 μ M or 5 μ M, indicating that intracellular CO release did not occur or was undetectable by this method. In contrast, RAW cells treated with 21b and 22b showed strong blue fluorescence in a dose-dependent fashion (Fig. 3c,d) , indicating CO release. The cells treated with either 21b or 22b alone showed no fluorescence (data not shown). In the case of the reaction between 21a and 22a, the first t 1/2 was roughly calculated to be around 397 h with an initial concentration of 5 μ M. Therefore, it was not surprising that cells treated with 21a and 22a for 3 h did not show any fluorescence. However, after conjugation with TPP, compounds 22b and 21b can be enriched in the mitochondria, and hence the local concentrations for 22b and 21b are substantially increased. Assuming that the concentrations of compound 21b and 22b were enriched to 400 μ M, we determined t 1/2 for the click reaction to be around 2 h. Consequently, one would expect cells treated with 21b and 22b to show strong blue fluorescence. The observed results are consistent with this analysis. To further confirm that CO release primarily occurred in mitochondria, RAW264.7 cells were co-treated with 22b (5 μ M) and 21b (2.5 μ M) for 4 h, followed by addition of the mitochondrial tracker MT-deep red for 20 min, and then imaged by confocal microscopy. As shown in Fig. 3e -h, the blue fluorescence (adjusted to green for ease of visualization) resulted from the click reaction between 21b and 22b, clearly co-localized with the MT-deep red mitochondrial tracker. Collectively, the results are consistent with CO release from the enrichment of 21b and 22b within mitochondria.
Assessment of the ability of the CO prodrug to exert anti-inflammatory effects in vitro.
Having confirmed that compounds 21b and 22b can be used for selective targeting of CO to mitochondria through an enrichment and release process, we next examined if such a strategy would be effective in recapitulating CO-associated biological responses 17, 18, 23 . Therefore, RAW264.7 macrophages were pretreated with compounds 21b and 22b at different concentrations for 4 h, and then challenged with bacterial lipopolysaccharide (LPS; 1 μ g ml −1 ) for 1 h. No decrease in cell viability was observed throughout the experiment. Cell supernatants were collected for tumour necrosis factor (TNF) expression determination by enzyme-linked immunosorbent assay (ELISA). Cells treated with 21a and 22a, or either compound 21b or 22b alone, were used as negative controls. Unlike co-treatment with 21a and 22a, co-treatment of 21b and 22b dose-dependently suppressed LPS-induced TNF expression. Importantly, no effects on TNF production were observed for RAW264.7 cells treated with 21a and 22a (without TPP conjugation) ( Supplementary Fig. 11 ). These data make clear that the observed TNF suppression is associated with the presence of CO generated on clicking 21b with 22b in the mitochondria. Inhibition of TNF by this mechanism of CO exposure mimicked that observed with gaseous CO, as reported in numerous earlier reports 17, 23, 48, 50, 51 . Furthermore, the remarkably low IC 50 value (~5 μ M) is the lowest we have seen of all the organic CO prodrugs tested under the same experimental protocols 17, 18 . For example, with organic CO prodrugs, we have seen IC 50 values in the 25-100 μ M range depending on the release t 1/2 (ranging from 2 min to 2 h). Of particular importance is the nearly complete suppression of TNF production at 10 μ M ( Supplementary Fig. 11 ), which has not been observed with any 
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previously tested organic CO prodrugs 17, 18 . These results further suggest the power of directly delivering CO to mitochondria.
Assessing the utility of the ETR system in vivo. To assess whether the concept of ETR would work in vivo and result in the intended pharmacological effect, we tested the CO prodrug system in a wellcharacterized in vivo model of acetaminophen (APAP)-induced acute liver injury where TNF is known to be involved and where inhaled CO gas has been shown to impart salutary effects when given after APAP and at a time when liver injury has already begun [52] [53] [54] . In this model, fasted male CD-1 mice were administered an overdose of APAP, which leads to rapid pro-inflammatory sequelae, ultimately resulting in massive hepatocyte cell death (Fig. 4 ). We reasoned that the described CO prodrug should match the hepatoprotection observed with inhaled CO. APAP injury occurs in two phases. The first is a rapid radical-mediated hepatocyte cell death that releases local inflammatory mediators. The second phase, which ultimately leads to liver failure, is a cytokine storm that results in massive hepatocyte death and has systemic implications 55, 56 . It is well known that the targets of CO are largely in the mitochondria 57 . Thus, we hypothesized that targeting CO release to mitochondria would lead to significant anti-inflammatory and anti-apoptotic effects. We next compared administering a combination of the TPP-conjugated CO prodrugs (21b + 22b) to their counterparts without the TPP unit and their ability to enrich (21a + 22a). Mice were treated with 21a and 22a or 21b and 22b. Controls received equivalent volumes of DMSO as the vehicle. Mice were administered APAP, followed 4 h later with 21b, then 3 min later by 22b at 4 mg kg −1 (intravenous, i.v.) or 0.4 mg kg −1 (i.v.) in separate groups. These animals were compared to those that received 21a plus 22a using identical treatment regimens. Serum and liver tissue were collected 24 h later and analysed for serum alanine aminotransferase (ALT) as a measure of liver injury, with immunostaining of liver sections for indices of cell death (TdT-mediated dUTP nick end labelling assay, TUNEL) and architectural changes (haemotoxylin and eosin, H&E). Both 21a + 22a and 21b + 22b showed significantly lower serum ALT levels relative to DMSO vehicle-treated animals in response to APAP (Fig. 4) , which is consistent with the literature-reported protective effects of CO 53 . At the higher 4 mg kg −1 dose the reduction in ALT achieved with 21a and 22a was 58%. In contrast, in animals treated with the TTP conjugates 21b and 22b known to enrich in the mitochondria, the reduction in serum ALT levels was > 95%. At a tenfold lower dose (0.4 mg kg −1 ), treatment with the TPP conjugates (21b and 22b) resulted in 55% reduction in serum ALT levels, compared to the non-TPP conjugated compounds (21a and 22a) , which had no effect on APAP-induced ALT levels. It should also be noted that treatment with 21b and 22b increased carboxyhaemoglobin levels, which is an important pharmacokinetic indicator for CO presence in the circulation (Fig. 4b ). Finally, histological staining analyses of the livers from these mice corroborated the serum ALT data, showing less cell death as measured by TUNEL and H&E in those animals treated wtih the 21b and 22b pair ( Fig. 4c-h) . Collectively, these results clearly show that TPP conjugation enhances local delivery of CO in a dose-dependent fashion that provides potent hepatoprotection. It should be noted that the molecular weights of the TPP conjugates (21b and 22b) are nearly twice those of the parent compounds (21a and 22a) . Thus, the same dose based on weight is half the dose when considering the molarity for the TPP conjugates. Taken together, these results demonstrate, in part, the proof of principle of the enrich-and-release concept in vivo for the effective delivery of CO to impart tissue cytoprotection.
Discussion
In targeted therapy there is a strong need for the development of new chemistry to achieve selective delivery to complement existing methods. In this study, we have developed and tested a new concept and platform approach, which relies on concentrationsensitive chemistry to allow for selective drug release following enrichment. This is achieved by taking advantage of reaction kinetics to allow for accelerated cleavage at an elevated concentration. This approach may prove very useful in delivering small molecules through targeting, including the use of antibody-drug conjugates 
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and receptor-mediated drug delivery. As a result, delivery is not limited to the cell surface and can be used for subcellular delivery with enriched concentrations, which has not been possible with ADCbased delivery. Collectively, we describe a method that could be leveraged for biological and medicinal efforts to treat disease. These compounds may be very useful therapeutics for the treatment of cancer and acute liver injury.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability. Additional details on the methods used and compound characterizations are provided in the Supplementary Information. Supplementary figures include 1 H NMR spectra of 21a at different temperatures ( Supplementary Fig. 1 ), schematic representations of the reaction between tetrazine 10 and alkyne 2 ( Supplementary Fig. 3 ), studies of reaction kinetics ( Supplementary  Figs. 4-6 ), CO myoglobin assay ( Supplementary Fig. 8 ), cytotoxicity assay ( Supplementary Figs. 9 and 10 ), ELISA assay ( Supplementary  Fig. 11 ) and NMR spectra of all synthesized compounds. The Supplementary tables include results of studies on reaction kinetics (Supplementary Tables 1-3 Table 4 ) and computational studies (Supplementary 
), stability tests (Supplementary
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Describe whether the experimental findings were reliably reproduced. Cell culture: cytotoxicity analysis and ELISA studies are very general assay and we exactly followed the protocol to do those assays. Animals: Acetaminophen toxicity is a standard model in our laboratory that we have used over the past 10 years and tested in hundreds of mice and highly reproducible liver injury.
Randomization
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Cell culture: Cell incubated in T75 flask were randomized separated incubated in 96-well-plate. Animals: Mice were randomized by having one researcher select the mice from the total group and handing them to the researcher performing the injections in the mice who was unaware of the cage origin and what was being administered.
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Cell culture:Three individuals participated in the experiments. Each of them performed the experiments at different times. Animals: Two individuals participated in the experiments. One was responsible for preparing the reagents and then selecting the mice and handing them to the second researcher who performed the injections.
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